ACP
BTAI icon

Acuta Capital Partners’s BioXcel Therapeutics BTAI Stock Holding History

Acuta Capital Partners’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-21,281
Closed -$18.1M – 50
2020
Q2 		$18.1M Buy
21,281
+1,593
+8% +$1.04M 5.22% 3
2020
Q1 		$7.04M Buy
+19,688
New +$7.08M 3.41% 12

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Acuta Capital Partners's BTAI Position: Q3 2020 in Review

Acuta Capital Partners sold out of BioXcel Therapeutics (BTAI) in Q3 2020, closing a stake of 21,281 shares — an estimated $18.1M sold.

Acuta Capital Partners first reported a position in BTAI in Q1 2020 and held it in 2 quarters. The position peaked at $18.1M in Q2 2020. 108 funds tracked by Wall St. Rank hold BTAI as of Q3 2020.

  • Acuta Capital Partners reported no remaining BioXcel Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Acuta Capital Partners sold 21,281 BioXcel Therapeutics shares in Q3 2020, an estimated $18.1M.
  • Acuta Capital Partners first reported a position in BioXcel Therapeutics in Q1 2020 and held it in 2 quarters.
  • Acuta Capital Partners's BioXcel Therapeutics position peaked at $18.1M in Q2 2020.
  • 108 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q3 2020.

Based on Acuta Capital Partners's 13F filing for Q3 2020, filed 16 Nov 2020.